New England Journal of Medicine , 393 , 2636.
Researchers say their findings mean that GLP-1s should be considered as a potential treatment for respiratory diseases
Recalls & Warnings June 26, 2024 FDA Warns Consumers Not to Use Infla-650 Due to Undeclared Drugs On June 20, 2024, the FDA warned consumers not to purchase or use Infla-650 after FDA laboratory analysis found them to contain acetaminophen, diclofenac, and phenylbutazone
This can be appealing to those who prefer something lighter
The antibody-drug conjugate (ADC), which was originally developed under a partnership between Seagen and Genmab, was granted accelerated approval in September 2021 based on a 24% objective response rate seen in the Phase II innovaTV 204 trial
All analyses were performed using reproducible data-processing scripts, with drug-specific analyses conducted independently